Therapy Initiation Resources

• Measures
  • Measure 114 – NK1 Receptor Antagonist (aprepitant, fosaprepitant, netupitant) or Olanzapine administered for low or moderate emetic risk Cycle 1 chemotherapy (Lower Score – Better)
  • Measure 115 – NK1 Receptor Antagonist and Olanzapine prescribed or administered with high emetic risk chemotherapy

Other Resources

• CINV Slides from 2022 Biannual Meeting
• CINV Slides from 2019 Biannual Meeting

Antiemetic Guidelines:

• ASCO
• NCCN
• MASCC/ESMO
• Comparison of Antiemetic Guidelines
• Choosing Wisely Antiemetic Recommendation

HOPA Time to Talk CINV Toolkit

ONS CINV Summary